BioMarin Pharmaceutical Inc., a global leader in providing therapies for rare genetic diseases, today announced the appointment of former Baxalta Chief Financial Officer and Chief Operations Officer, Robert J. Hombach, to its Board of Directors.
“We are thrilled to have Bob join BioMarin’s Board of Directors. He brings additional expertise in financial and operational management in the biopharmaceutical industry to an already outstanding board,” said Jean-Jacques Bienaimé, Chairman and Chief Executive Officer at BioMarin. “I am confident he will make meaningful contributions to support BioMarin’s growth as we continue to develop pioneering therapies for patients with rare genetic diseases.”
“I am honored to serve on the board of a company with a 20-year history of developing therapies that make a big difference for small patient populations,” said Robert J. Hombach. “I am looking forward to working with BioMarin as it continues to build its current business, while advancing a robust pipeline during a time of exceptional growth.”
Coeliac disease causes long-term damage to patients’ small intestine and puts them at risk of other medical conditions. Treatment options are urgently needed. Allie Nawrat explores the promise of larazotide, the drug in development currently leading the pack.
Bone Therapeutics has announced positive 24-month follow-up results from its phase IIa study of Allob, its allogeneic cell therapy, in patients undergoing lumbar spinal fusion procedures.
Belgian pharma company UCB has agreed to acquire a new campus to further support its operations in the UK.